CATX
HEALTHCAREPerspective Therapeutics Inc
$3.82+0.17 (+4.66%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving CATX Today?
No stock-specific AI insight has been generated for CATX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.96$6.16
$3.82
Fundamentals
Market Cap$436M
P/E Ratio—
EPS$-1.41
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding114.0M
CATX News
21 articles- 4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Perspective Therapeutics to Provide Several Upcoming Corporate UpdatesYahoo Finance·Apr 24, 2026
- Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightGlobeNewswire Inc.·Apr 20, 2026
- Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual MeetingGlobeNewswire Inc.·Apr 20, 2026
- Perspective Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc.·Apr 2, 2026
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026Yahoo Finance·Mar 17, 2026
- Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 ResultsYahoo Finance·Mar 16, 2026
- Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial ProgressYahoo Finance·Feb 18, 2026
- Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial ResultsYahoo Finance·Feb 17, 2026
- Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed?Yahoo Finance·Feb 4, 2026
- Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Feb 2, 2026
- A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline UpdatesYahoo Finance·Feb 2, 2026
- Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 12, 2026
- Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers SymposiumYahoo Finance·Jan 9, 2026
- Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 18, 2025
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers SymposiumYahoo Finance·Dec 4, 2025
- Perspective Therapeutics to Participate in Upcoming December ConferencesYahoo Finance·Nov 20, 2025
- Perspective Therapeutics: Q3 Earnings SnapshotYahoo Finance·Nov 10, 2025
- Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 ResultsYahoo Finance·Nov 10, 2025
- Stevanato Group (STVN) Q3 Earnings and Revenues Surpass EstimatesYahoo Finance·Nov 6, 2025
- Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue EstimatesYahoo Finance·Nov 4, 2025
All 21 articles loaded
Price Data
Open$3.65
Previous Close$3.65
Day High$3.91
Day Low$3.57
52 Week High$6.16
52 Week Low$1.96
52-Week Range
$1.96$6.16
$3.82
Fundamentals
Market Cap$436M
P/E Ratio—
EPS$-1.41
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding114.0M
About Perspective Therapeutics Inc
Perspective Therapeutics Inc. (CATX) is an innovative biotechnology company dedicated to transforming cancer treatment through the development of advanced radiopharmaceuticals. Harnessing cutting-edge radioisotope technologies, CATX aims to improve the precision and efficacy of cancer therapies, ultimately enhancing patient survival rates across a spectrum of malignancies. With a robust leadership team and strategic partnerships, the company is well-positioned to spearhead breakthroughs in targeted cancer treatments, addressing critical healthcare needs in a highly competitive sector.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—